Ruth Keri, PhD, Associate Director for Basic Research at the Case Comprehensive Cancer Center and Professor of Cancer Biology at Cleveland Clinic, joins the Cancer Advances Podcast to talk about her research on a promising new target for treating triple-negative breast cancer, YES1 inhibitors. Listen as Dr. Keri shares the potential of YES1 inhibitors in improving the effectiveness of chemotherapy and the clinical trials that are underway to assess the safety and effectiveness of these inhibitors.
Ruth Keri, PhD, Associate Director for Basic Research at the Case Comprehensive Cancer Center and Professor of Cancer Biology at Cleveland Clinic, joins the Cancer Advances Podcast to talk about her research on a promising new target for treating triple-negative breast cancer, YES1 inhibitors. Listen as Dr. Keri shares the potential of YES1 inhibitors in improving the effectiveness of chemotherapy and the clinical trials that are underway to assess the safety and effectiveness of these inhibitors.